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After the expiration of patents on originator biological products, Jordanian local manufacturers and the
agents of international pharmaceutical companies in Jordan started to submit registration dossiers for
biosimilar products. The Jordan Food and Drug Administration (JFDA) is the national regulatory authority
responsible for the registration of biosimilar products. Biosimilars are registered under the same regu-
lations used for drugs until speciﬁc guidelines for registration of biological and biosimilar products are
released. Those regulations are called Criteria of Registration of Drugs, Vaccines, Sera and Biological
Products, the Renewal of its Registration and the Cancellation of Any of themwhich was published in the
ofﬁcial gazette in 2004 under the Provisional Law Number 80 of the year 2001, Drug and Pharmacy Law
and its amendments of the year 2003. Also, the JFDA follows the EMA guidelines on similar biological
medicinal products for speciﬁc active biological substances for non-clinical and clinical studies
requirements and the EMA guideline on similar biological medicinal products containing biotechnology-
derived proteins as active substance: quality issues. A post marketing surveillance study is requested
after a biosimilar product is authorized.
The JFDA keeps pace with all advances in the regulatory issues related to biosimilars in order to be
capable of authorizing biosimilar products with a safe, effective and good quality proﬁle.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
The prevalence of type 2 diabetes mellitus and impaired glucose
tolerance is increasing in Jordan [1] making insulin one of the most
important biotherapeutic products in the Jordanianmarket as is the
case worldwide. Anti-cancer biological products are considered
another group of important biotherapeutic products since cancer is
the second most frequent cause of death after heart disease in
Jordan [2]. A total of (4606) new cases of cancer among Jordanians
were registered in 2008 [3] compared to a total of (3678) new cases
registered in 2005 [4]. These data show the increased burden on
the government and patients regarding healthcare expenditure
taking into account the high cost of originator biological products.
After the expiration of patents on originator biological products,
and taking into consideration that in 2013e2015 it is estimated that
several biological products representing US $20 billion in annual
sales are anticipated to lose patent protection [5], Jordanian localfax: þ962 65105916/þ962
n_rania@yahoo.com.
ll rights reserved. The World Healthmanufacturers and agents of international pharmaceutical
companies started to submit registration dossiers for biosimilar
products so as to provide the local pharmaceutical market with
biological products with competitive prices compared to the
expensive reference biological products (RBP). However, there is
a concern that, because biosimilars may not be considered inter-
changeable nor substitutable with their reference/originator
products and due to the high cost of developing biosimilars, cost
savings to patients using biosimilars will be minimal [6].
Jordan has been a member in the World Trade Organization
(WTO) since 2000 and the Jordanian Law of Unfair Competition and
Trade Secrets No. 15 of 2000 was issued consistent with WTO
agreement on Trade-Related aspects of Intellectual Property Rights
(TRIPS). According to this law, data protection for new chemical
entities lasts 5 years [7] provided that the registration dossier of the
product to be protected is submitted to Jordanian regulatory
authority within 18 months of its ﬁrst date of registration inter-
nationally [8] and the same applies to biological products.
Until now there is no local manufacturer that started developing
its own biosimilar product. Only one local manufacturer is working
on a biosimilar product where the bulk material was bought from
a foreign manufacturer and will be formulated into the ﬁnal
product in Jordan. Other manufacturers are contract manufacturingOrganization has granted the Publisher permission for the reproduction of this article.
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and batch release step will be done in Jordan.2. Products information: current situation
Only one product was authorized as a biosimilar in 2009. Ten
biosimilar products have been ﬁled in 2008, 2009 and 2010, nine of
which are under review. On the other hand, one product which was
submitted in 2005 has failed our approval process in 2009 due to
incomplete clinical and quality data.3. Legislative basis and approach
The Jordan Food and Drug Administration (JFDA) was estab-
lished in 2003 as the sole national competent authority for drug
safety and efﬁcacy and food safety and quality. It is divided into two
main directorates, the Drug Directorate and Food Directorate, in
addition to other supporting directorates. The Registration
Department, which is part of the drug directorate, is responsible for
registering drugs according to approved guidelines set by the Prime
Minister and published in the ofﬁcial gazette.
There are several working committees in the drug directorate
which are formulated according to the Provisional Law Number 80
of the year 2001, Drug and Pharmacy Law and its amendments of
the year 2003 [9]. The Technical Committee for the Registration of
New Drugs is the committee responsible for registration of origi-
nator, new drugs and biological and biosimilar products. The
chairman of this committee is the secretary general of the Minister
of Health and the vice chairman is the director of the drug direc-
torate. Its main responsibilities are to authorize new drugs and
study any updates regarding drugs safety and uses and to make
decisions concerning different safety, efﬁcacy and quality issues.
At present, biosimilar products are registered under the same
regulations used for drugs. Those regulations are called Criteria of
Registration of Drugs, Vaccines, Sera and Biological Products, the
Renewal of its Registration and the Cancellation of Any of them
which was published in the ofﬁcial gazette in 2004 under the
Provisional Law Number 80 of the year 2001, Drug and Pharmacy
Law and its amendments of the year 2003. However, the registra-
tion of Biological and Biosimilar Products differs from the regis-
tration of conventional drugs in the following ways:
- The manufacturing site/sites of the active ingredient/s and
intermediate product/s must be accredited.
- For biosimilars, comparative non-clinical, clinical and quality
requirements must be met (according to EMA guidelines).
- Batch record of three consecutive batches of the ﬁnished
product must be submitted.
It should be noted that Jordan is presently implementing the
Common Technical Document (CTD).
According to article 9-a of the Criteria of Registration of Drugs,
Vaccines, Sera and Biological Products, the Renewal of its Regis-
tration and the Cancellation of Any of them: “The Committee
decides on any application for registering new drugs and the drugs
that have a registered equivalent. It does this within a maximum
period of one hundred and eighty days (180) from the date of the
submission of the application of completed documents to the
Directorate”, provided that the applicant submitted all requested
data. In addition, according to article 9-b: “The Committee decides
on any application of completed documents for registration of
equivalent drugs the information of which is protected or which is
protected by a Patent Right within a maximum period of 180 days
before the expiry of the protection, provided that the resolutionfor registration is issued on the next day of the expiry of
protection”.
Prior to 2006, a few noneinnovator products were registered as
generic medicines. In 2008 the JFDA started to review them as
biosimilars. For registration as biosimilars, dossiers are reviewed
and evaluated by referring to the EMA guidelines on similar bio-
logical medicinal products for speciﬁc active biological substances
(e.g. recombinant human soluble insulin) as our reference for non-
clinical and clinical studies requirements for demonstration of
similarity in terms of safety and efﬁcacy between the reference
biological product (RBP) and the biosimilar product. Also, we follow
the EMA guideline on similar biological medicinal products con-
taining biotechnology-derived proteins as active substance: quality
issues, in order to be able to demonstrate that the biosimilar
product has a quality proﬁle similar to the reference product.
In order to monitor the safety and to ensure continuous
beneﬁt-risk evaluation of the authorized biosimilar product,
a post marketing surveillance study is requested after its release
in the Jordanian market. This is considered to be mandatory
especially since until now no clinical studies were done in
Jordan because by contract manufacturers. Local manufacturers
depended on the same clinical trials conducted by the
contractor. The choice of reference biological product is based on
the international registration date of a particular product (the
ﬁrst product registered internationally with a particular active
ingredient). Once a biosimilar product is authorized, it is not
considered as a RBP. There is still debate regarding inter-
changeability and substitutability of the biosimilar product with
the RBP as is the case worldwide [6].4. Jordanian guidelines and WHO guidelines/plan to
implement WHO guidelines
We are working on draft guidance for registration of biological
and biosimilar products. Our references are EMA guidance, ICH
guidelines and WHO guidelines. The experience we are gaining
from evaluating the registration dossiers of biosimilars submitted
to the JFDA and lessons learnt from our practice are considered
a good background for developing our own guidelines. It is
expected that the Jordanian biosimilars guidelines will differ from
WHO guidelines with respect to issues speciﬁc to Jordanian regu-
lations since WHO guidelines offer a basis for countries on which
each country can develop its own guidelines. For example there is
a difference in the choice of the RBP where in Jordan we consider
the RBP, as mentioned above, as the ﬁrst product registered inter-
nationally with a particular active ingredient, while WHO gives
a general deﬁnition only. Also we refer to the EMA guidelines for
non-clinical and clinical studies requirements for speciﬁc active
biological substances.5. Conclusion
In conclusion, the Jordan Food and Drug Administration, as
a regulatory authority shares the same concerns and challenges of
other regulatory authorities in the biosimilar products registration
ﬁeld, and will keep pace with all updates and advances in the
regulatory issues related to biosimilars in order to be capable of
authorizing biosimilar products with a safe, effective and good
quality proﬁle.
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